

Contract Development and Manufacturing (CDMO) Market - 2024-2033

<https://marketpublishers.com/r/CA6C386E3B2AEN.html>

Date: January 2026

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: CA6C386E3B2AEN

Abstracts

The Contract Development and Manufacturing (CDMO) Market was valued at US\$ 150.19 billion in 2024 and is anticipated to reach US\$ 280.07 billion by 2033, at a CAGR of 0.074 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Contract Development and Manufacturing (CDMO) Market.

This report delivers a comprehensive overview of the Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Contract Development and Manufacturing (CDMO) Market. The Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Contract Development and Manufacturing (CDMO) Market Scope:

By Service Type

Active Pharmaceutical Ingredient (API) Manufacturing

Finished Dosage Formulation (FDF) Development and Manufacturing

Secondary Packaging

By Research Phase

Pre-Clinical

Phase I

Phase II

Phase III

Phase IV

By End-User

Pharmaceutical Companies

Contract Research Organizations (CROs)

Generic Pharmaceutical Companies

Key Players

Catalent Inc

Recipharm AB

Jubilant Pharmova Limited

Thermo Fisher Scientific Inc.

Boehringer Ingelheim International GmbH

IQVIA

Syneos Health

Parexel International (MA) Corporation

Curia Global, Inc.

NextPharma Technologies

Major Highlights

This report delivers a comprehensive overview of the Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Contract Development and Manufacturing (CDMO) Market. The Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Service Type
- 3.2. Snippet by Research Phase
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.2. Rising Demand for Pharmaceutical and Biopharmaceutical Products
 - 4.1.3. Restraints
 - 4.1.4. Stringent Regulatory Requirements
 - 4.1.5. Opportunity
 - 4.1.6. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion

6. BY SERVICE TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type

6.1.2. Market Attractiveness Index, By Service Type

6.2. Active Pharmaceutical Ingredient (API) Manufacturing*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Finished Dosage Formulation (FDF) Development and Manufacturing

6.4. Secondary Packaging

7. BY RESEARCH PHASE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase

7.1.2. Market Attractiveness Index, By Research Phase

7.2. Pre-Clinical*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Phase I

7.4. Phase II

7.5. Phase III

7.6. Phase IV

8. BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Pharmaceutical Companies*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Contract Research Organizations (CROs)

8.4. Generic Pharmaceutical Companies

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Service Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. The U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Service Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. UK

9.3.6.3. France

9.3.6.4. Italy

9.3.6.5. Spain

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Service Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Service Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 9.5.6.1. China
- 9.5.6.2. India
- 9.5.6.3. Japan
- 9.5.6.4. South Korea
- 9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Service Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Research Phase
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

- 11.1. Catalent Inc*
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Financial Overview
 - 11.1.4. Key Developments
- 11.2. Recipharm AB
- 11.3. Jubilant Pharmova Limited
- 11.4. Thermo Fisher Scientific Inc.
- 11.5. Boehringer Ingelheim International GmbH
- 11.6. IQVIA
- 11.7. Syneos Health
- 11.8. Parexel International (MA) Corporation
- 11.9. Curia Global, Inc.
- 11.10. NextPharma Technologies (LIST NOT EXHAUSTIVE)

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: Contract Development and Manufacturing (CDMO) Market - 2024-2033

Product link: <https://marketpublishers.com/r/CA6C386E3B2AEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA6C386E3B2AEN.html>